Carregant...
Tocilizumab and Thromboembolism in COVID-19: A Retrospective Hospital-Based Cohort Analysis
Background Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, has been used in patients with coronavirus disease 2019 (COVID-19) as an anti-cytokine agent. IL-6 also plays a complex role in hemostasis and thrombosis. We observed a transient elevation of D-dimer in our patients who received to...
Guardat en:
| Publicat a: | Cureus |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Cureus
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8220488/ https://ncbi.nlm.nih.gov/pubmed/34178527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.15208 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|